source
- Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
- Medtronic recalls Harmony delivery catheter system after tip detachment riskMedtronic has issued a recall of certain lots of its Harmony Delivery Catheter System (DCS), which is used to implant the Harmony transcatheter pulmonary valve. The FDA classified the recall as th…